Literature DB >> 32454668

Biopharmaceutical Process of Diclofenac Multi-particulate Systems for Chronotherapy of Rheumatoid Arthritis.

Sowjanya Battu1, Prasanna Raju Yalavarthi2, Subba Reddy Gv3, Saradha Radhakrishnan1, Ram Mohan Reddy Thummaluru1, Abbulu Konde1.   

Abstract

OBJECTIVES: Diclofenac exhibits limited solubility, low bioabsorption and gastric toxicity. The objective of the study was to address the above limitations and to design a multi-particulate formulation for the chronotherapy of RA.
MATERIALS AND METHODS: Solid dispersions of DC with SSG and GG were prepared. Uniform-sized (∼400 µm) non-pareil seeds were coated with solid dispersions to produce immediate-release pellets (DMP-1 and DMP-2) and controlled-release pellets (DMP-3 and DMP-4). The resultant controlled-release pellets were further layered with methacrylate polymers to obtain pulsatile-release pellets (DMPP). Solubility, FTIR, DSC, micrometrics, SEM, drug content, drug release, pharmacokinetics, and stability studies were performed for DMPP.
RESULTS: The solubility of DC was improved by 164-folds due to the presence of hydrophilic carriers in the solid dispersions. No chemical and physical interactions were noticed in FTIR spectra and also in thermograms. A fluidized bed processor facilitated the production of high-quality, circular, and regular pellets with an angle of repose less than 19.5 degrees and DC content between 95.18% and 98.87%. The maximum drug was released from DMPP at the end of 12 hours. DMP-1 and DMP-2 pellets had 2 hr of drug release and pulsatile, controlled-release pellets had a 6 hr lag phase followed by 12 hr controlled release. Both DMP-1 and DMP-2-immediate showed first-order release followed by Hixson-Crowell kinetics, whereas DMPP pellets followed zero-order release with Higuchi's kinetics. The maximum concentration of DC in plasma was 400.8 ng/mL at 5 hr for DMP-2 and 381.1 ng/mL at 14 hr for DMPP-5. The solubility of DC was increased with the application of solid dispersion and in turn increased the pharmacokinetics. The pellets were plausibly stable over a period of 90 days.
CONCLUSION: Thus, multi-particulate pulsatile systems of DC were as effective as chronotherapeutics in the treatment of circadian rhythm-based ailments such as RA. ©Copyright 2018 Turk J Pharm Sci, Published by Galenos Publishing House.

Entities:  

Keywords:  Chronomodulation; NSAID; Wurster process; circadian; fluidized bed; hydrophilic carrier

Year:  2018        PMID: 32454668      PMCID: PMC7227835          DOI: 10.4274/tjps.92400

Source DB:  PubMed          Journal:  Turk J Pharm Sci        ISSN: 1304-530X


  18 in total

Review 1.  Pelletization processes for pharmaceutical applications: a patent review.

Authors:  Stavros N Politis; Dimitrios M Rekkas
Journal:  Recent Pat Drug Deliv Formul       Date:  2011-01

2.  Should we switch from analgesics to the concept of "Pain Modifying Analgesic Drugs (PMADs)" in osteoarthritis and rheumatic chronic pain conditions?

Authors:  Serge Perrot
Journal:  Pain       Date:  2009-08-19       Impact factor: 6.961

3.  Design and in vitro/in vivo evaluation of extended release matrix tablets of nateglinide.

Authors:  Pushkar R Sharma; Shaila A Lewis
Journal:  J Young Pharm       Date:  2013-12-11

4.  Physical activity, cystic erosions, and osteoporosis in rheumatoid arthritis.

Authors:  B A Castillo; R A el Sallab; J T Scott
Journal:  Ann Rheum Dis       Date:  1965-11       Impact factor: 19.103

5.  Microparticles produced by the hydrogel template method for sustained drug delivery.

Authors:  Ying Lu; Michael Sturek; Kinam Park
Journal:  Int J Pharm       Date:  2013-12-11       Impact factor: 5.875

Review 6.  DREAMing about arthritic pain.

Authors:  H-Y M Cheng; J M Penninger
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

7.  Solid self microemulsification of Atorvastatin using hydrophilic carriers: a design.

Authors:  R Nanda Kishore; Prasanna Raju Yalavarthi; Harini Chowdary Vadlamudi; K R Vandana; Arun Rasheed; M Sushma
Journal:  Drug Dev Ind Pharm       Date:  2014-07-14       Impact factor: 3.225

Review 8.  Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews.

Authors:  Kurt Kroenke; Erin E Krebs; Matthew J Bair
Journal:  Gen Hosp Psychiatry       Date:  2009-03-04       Impact factor: 3.238

9.  Pain threshold and arthritis.

Authors:  E C Huskisson; F D Hart
Journal:  Br Med J       Date:  1972-10-28

10.  Formulation development and evaluation of alginate microspheres of Ibuprofen.

Authors:  M Nagpal; Dk Maheshwari; P Rakha; H Dureja; S Goyal; G Dhingra
Journal:  J Young Pharm       Date:  2012-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.